Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced that a plixorafenib abstract has been ...

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on ...

LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

LUT014, a topical BRAF-inhibiting gel, may mitigate acneiform rash in patients receiving EGFR-targeted therapy for colorectal cancer, according to phase II clinical trial results presented by Anisha B ...

Additionally, NRX-0305, a BRAF degrader, showed broad efficacy across all three mutation classes of BRAF, with significant anti-tumor activity in resistant tumors. The company is also developing ...

The research highlights significant findings and the progress of plixorafenib in treating patients with BRAF-mutated cancers. One presentation will showcase data demonstrating that circulating ...

Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory ...